Science Corporation implants vision-restoring chip in first Stargardt disease patient
Science Corporation has successfully implanted its PRIMA vision-restoring chip in a patient with Stargardt disease, a condition that leads to central vision loss. This marks a significant step in the company's broader goal of developing brain-computer interface technologies for various medical applications.
Science Corporation's CEO Max Hodak announced the implantation of the PRIMA chip in its first Stargardt disease patient at TechCrunch Disrupt.
Stargardt disease is an inherited eye condition that progressively destroys central vision, affecting around 150,000 people globally. The PRIMA chip, which is already available in Europe for other vision impairments, aims to restore sight by simulating photoreceptor function in the eye.
The first patient received the implant in May during a trial at the Sydney Eye Hospital and has already shown some ability to see letters and words during rehabilitation sessions.
The procedure involves placing a small chip in the back of the eye, complemented by camera-equipped glasses that transmit visual information to the chip. The current device provides limited black-and-white vision but is expected to improve over time with advancements in technology.
Hodak emphasized the potential for brain-computer interfaces to address various neurological conditions and indicated plans for future developments in this area, including applications for neurodegenerative diseases and stroke recovery. He envisions a future where BCIs become common for older adults to enhance health and longevity.